Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Iovance updated full-year 2026 revenue guidance, signaling a changed outlook for investor expectations.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Iovance updated full-year 2026 revenue guidance, signaling a changed outlook for investor expectations
- Exhibit 99.1 contains the revised revenue outlook and supporting details
- Guidance revision may affect valuation, earnings estimates, and near-term share-price volatility
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue guidance raised to $410–$420 million from $350–$370 million
- New midpoint up $55 million, approximately 15%, implying nearly 60% annual revenue growth
- Strong U.S. demand for Amtagvi and Proleukin supports the increased outlook
- Q2 2026 product revenue reached $99.3 million, with manufacturing visibility supporting third- and fourth-quarter expectations
- Authorized treatment center network near 100, targeting at least 110 by year-end 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.